NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Cash from Operating Activities
NAYA Biosciences Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Cash from Operating Activities
-$3.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Operating Activities
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Operating Activities
$8.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Operating Activities
$1.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-3.1m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Cash from Operating Activities amounts to -3.1m USD.
What is NAYA Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
21%
Over the last year, the Cash from Operating Activities growth was 39%. The average annual Cash from Operating Activities growth rates for NAYA Biosciences Inc have been 21% over the past three years .
You don't have any saved screeners yet